Next generation immunotherapies for hard-to-treat cancers.
AvenCell Therapeutics is a clinical-stage biopharma developing next-generation allogeneic and switchable CAR-T cell therapies for hard-to-treat cancers. Their proprietary platforms enable precise targeting, controllability, and safety, overcoming limitations of current immunotherapies. Backed by leading investors, they focus on advancing immunotherapies to improve patient outcomes globally.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account